Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Losartan Potassium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SCIENTURE Gains FDA Nod for SCN-102, Branded as Arbli (Losartan Suspension)
Details : Arbli (losartan potassium) is an angiotensin II receptor blocker indicated for hypertension, to lower blood pressure in adults and children greater than 6 years old.
Product Name : Arbli
Product Type : Hormone
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : Losartan Potassium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Summit Biosciences
Deal Size : Undisclosed
Deal Type : Agreement
Scienture, Kindeva Launch REZENOPY® for Opioid Overdose Treatment
Details : Under the agreement, Scienture will own the NDA for Rezenopy (Naloxone HCl) in its name and be responsible for the sales, marketing and distribution of the product in the US.
Product Name : Rezenopy
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 06, 2025
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Summit Biosciences
Deal Size : Undisclosed
Deal Type : Agreement